ConforMIS (CFMS) Shares are Up 15.39%

ConforMIS (CFMS) : Traders are bullish on ConforMIS (CFMS) as it has outperformed the S&P 500 by a wide margin of 17.5% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 14.78%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 15.39% in the last 1 week, and is up 15.12% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 16.88% and the 50-Day Moving Average is 24.42%.The 200 Day SMA reached 7.64% ConforMIS, Inc. is up 36.01% in the last 3-month period. Year-to-Date the stock performance stands at -44.07%.


ConforMIS (CFMS) : 3 Wall Street analysts covering ConforMIS (CFMS) believe that the average level the stock could reach for the short term is $17. The maximum price target given is $26 and the minimum target for short term is around $12, hence the standard deviation is calculated at $7.81.

For the current week, the company shares have a recommendation consensus of Buy. ConforMIS (NASDAQ:CFMS): The stock opened at $8.75 and touched an intraday high of $9.83 on Friday. During the day, the stock corrected to an intraday low of $8.73, however, the bulls stepped in and pushed the price higher to close in the green at $9.67 with a gain of 12.31% for the day. The total traded volume for the day was 1,626,888. The stock had closed at $9.67 in the previous trading session.

ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, to fit each patients anatomy. It is engaged in offering a line of customized knee implants designed to restore the natural shape of a patients knee. The Company has sold over 30,000 knee implants in the United States and Europe. It also launched iTotal PS, the Companys posterior-stabilized total knee replacement implant, which addresses the largest segment of the knee replacement market. The Companys products are available in the United States, Germany and the United Kingdom. Its products are offered to orthopedic surgeons, hospitals and other medical facilities and patients. The Companys iFit technology platform includes three elements: iFit Design, iFit Printing and iFit Just-in-Time Delivery.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.